Pfizer Raises 2021 Forecast, But Sees Shot Sales Falling Next Year
- Sales of shots seen topping estimates next year at $29 billion
- CEO urges low- and middle-income countries to place orders
This article is for subscribers only.
Pfizer Inc. raised its full-year forecast on the strength of Covid-19 vaccine sales and provided its first glimpse at potential gains for 2022, projecting $29 billion in sales from the shot it developed with BioNTech SE.
Pfizer executives cautioned that the estimate, based on existing contracts for 1.7 billion doses, is conservative, as the partners have capacity to make as many as 4 billion shots next year. Many countries have yet to make purchases, and new customers could include private buyers, executives said.